

Antibiotics

“Shorter is Better”



McGill Refresher Course 2022
Trong Tien Nguyen, MDCM, FRCPC
Infectious Diseases & Medical Microbiology

Speaker / Disclosures


- Trong Tien Nguyen, MDCM, FRCPC
 - Infectious Diseases & Medical Microbiology
 - St. Mary's Hospital, CIUSSS ODIM
- Speaker has no conflict of interest.

Learning Objectives

As a result of attending this session, participants will be able to:

- Avoid prescribing antimicrobials when they are not clinically indicated.
- Safely shorten antimicrobial courses in order to reduce their adverse consequences.
- Recognize clinical situations when shortening antimicrobials is not warranted.

WHY SHORTER?



Adverse Drug Events Occur in 20% Patients on Antibiotics

- Common & serious adverse effects
 - Gastrointestinal (42%)
 - Renal (24%)
 - Hematologic (15%)
 - *Clostridium difficile* infection
- Societal burden
 - Drug costs
 - Emergency department visits, hospital readmission
 - Emergence of resistant bacteria

Guidelines recommend many antibiotic options

- Alternatives allow individualized therapy
 - Allergies and intolerances
 - Contraindications
 - Resistance
- If options are equal, select the least harmful
 - Shorter duration
 - Less adverse effects
 - Less frequent dosing
 - Less expensive

(When they are not clinically indicated ...)

NO ANTIMICROBIALS IS BEST

“No matter how popular they get,
antibiotics will never go viral.”




<i>Influenza</i>	Rarely
<i>Rhinovirus</i>	<i>B. pertussis</i>
<i>Adenovirus</i>	<i>Mycoplasma</i>
<i>HMPV</i>	<i>pneumoniae</i>
<i>Coronavirus</i>	<i>Chlamydophila</i>
<i>Parainfluenza</i>	<i>pneumoniae</i>
<i>RSV</i>	



Don't prescribe
antibiotics in adults
with uncomplicated:


- Bronchitis
- Bronchiolitis
- Acute sinusitis
- Pharyngitis
- Acute otitis media

Antibiotics do not treat viruses



Don't use antibiotics for upper respiratory infections that are likely **viral** in origin, such as influenza-like illness, or self-limiting, such as **sinus infections of less than seven days** of duration.

– College of Family Physicians of Canada



Don't routinely use antibiotics in adults and children with **uncomplicated sore throats**.

– Canadian Association of Emergency Physicians



Don't use antibiotics in adults and children with **uncomplicated acute otitis media**.

– Canadian Association of Emergency Physicians

Acute rhinosinusitis is usually viral

- Resolves within 10-14 days, without treatment
- Consider antibiotics if:
 - Persistent & not improving ≥ 10 days
 - Severe symptoms $\geq 3-4$ days (fever, facial pain, purulent nasal discharge)
 - Worsening or double-sickening $\geq 3-4$ days



>70%, if bacterial

S. pneumoniae

H. influenzae


Rarely

M. catarrhalis

S. pyogenes

S. aureus

Bronchitis is usually viral

 Don't prescribe antibiotics in adults with bronchitis / asthma and children with bronchiolitis.

– Canadian Association of Emergency Physicians



Influenza

Rhinovirus

Adenovirus

Coronavirus

RSV

Rarely

B. pertussis

Mycoplasma

pneumoniae

Chlamydomphila

pneumoniae

Simple AECOPD Results in Additional Pharmacologic Therapy



S. pneumoniae
H. influenzae
M. catarrhalis

Bacterial
AECOPD



Purulent
sputum



↑
dyspnea

OR

↑
sputum
quantity

AECOPD Management Does Not Always Require Antibiotics

- GOLD guidelines (2019)
 - Mild: short-acting bronchodilators only
 - Moderate: [mild] + antibiotics +/- corticosteroids
 - Severe: [moderate] + hospitalization
- Cochrane SR/MA (2018)
 - ICU: ↓ mortality, ↓ LOS
 - Non-ICU:
 - Inconsistent effect on treatment failure
 - No benefit for mortality or LOS

Drained minor skin abscesses may not require antimicrobials

- Don't prescribe antibiotics after **incision and drainage** of uncomplicated skin abscesses unless extensive cellulitis exists.
 - Canadian Association of Emergency Physicians



S. aureus

>>>

S. pyogenes

Urinary tract infection diagnosis relies on clinical symptoms

- Fever
- Dysuria
- Frequency
- Urgency
- Suprapubic pain
- Costovertebral pain

- Acute hematuria
- New onset incontinence
- Rigors
- Altered mental status without other cause
- Increased spasticity or autonomic dysreflexia if spinal cord injury

- Cloudy urine
- Foul smelling urine

- Urinary retention
- Perineal pruritus



Symptom- Free Pee: LET IT BE

A national initiative to stop inappropriate antibiotic use for asymptomatic bacteriuria in long-term care residents.



For more direction and guidance:
www.ammi.ca
#SymptomFreeLetItBe



Do Not Screen for or Treat ASB



“Don’t use antimicrobials to treat **asymptomatic bacteriuria.**”

- Canadian Geriatrics Society
- Canadian Society for Hospital Medicine
- Canadian Urological Association
- Canadian Nurses Association
- American Geriatrics Society
- Infectious Diseases Society of America
- Canadian Association of Physical Medicine and Rehabilitation



“Don’t perform **urinalysis or urine culture** unless patients have signs or symptoms of infection.”

- American Academy of Pediatrics
- Society for Healthcare Epidemiology of America
- Long Term Care Medical Directors Association of Canada
- AMDA – The Society for Post-Acute and Long-Term Care Medicine

Urine Culture Should Not be Sent for Asymptomatic Bacteriuria (ASB)


- Prospective studies in long-term care facilities¹
 - Prevalence 10-50%
 - New pyuria/bacteriuria within 4 days of catheter
 - ASB can persist up to 1–2 years
 - No increased morbidity or mortality
- Up to 2/3 patients with ASB still receive antimicrobial therapy²

1. High KP. Clin Infect Dis. 2009

2. Leis JA. Clin Infect Dis. 2014

(When they are clinically indicated ...)

SHORTER IS BETTER



Upper Respiratory Tract Infection

- Otitis media
- Rhinosinusitis
- Bronchitis

Lower Respiratory Tract Infections

- Pneumonia
- Acute exacerbation
of COPD

Skin & Soft Tissue Infection

- Nonpurulent
cellulitis
- Purulent cellulitis

Urinary Tract Infection

- Cystitis
- Pyelonephritis
- Prostatitis

Treat Uncomplicated ENT Infections for 5-7 Days

Odontogenic

Penicillin +/-
metronidazole


Cephalosporin I/II
Amoxicillin +/- clavulanate
Clarithro-/Azithromycin*
Clindamycin

Rhinogenic

Amoxicillin +/-
clavulanate

Cephalosporin II
Ceftriaxone
Moxi-/Levofloxacin
+/- Vancomycin

**S. pneumoniae* azithromycin resistance in Quebec is ~20%.



Epidermis

- Erysipelas

Dermis

- Cellulitis

Hypodermis

- Abscess

Deeper Soft
Tissues

- Fasciitis, tenosynovitis
- Pyomyositis
- Osteomyelitis

Treat Uncomplicated SSTI for 5-10 days



Nonpurulent

S. pyogenes

>>>

S. aureus

Purulent

S. aureus

>>>

S. pyogenes


- First-line
 - Cefadroxil
 - Cephalexin
 - Cloxacillin
- INESSS (2017)
 - 5-10 days
- IDSA (2014)
 - 5 days (extend if not improved)

INESSS. 2017

Stevens DL. Clin Infect Dis. 2014

Choosing Wisely Canada. 2019

Lobar pneumonia is usually bacterial



S. pneumoniae

H. influenzae

K. pneumoniae

Legionella

M. tuberculosis

Treatment duration is individualized based on clinical response

- Body temperature $\leq 37.8^{\circ}\text{C}$ for ≥ 48 hours
- No supplemental oxygen
- ≤ 1 CAP-associated sign of clinical instability
 - HR > 100
 - RR > 24
 - SBP ≤ 90

Pneumonia Treatment can Safely be Shortened

- Trend to shorten courses
 - IDSA (2007) ≥ 5 days (stop using clinical criteria)¹
 - ≤ 7 days no different than >7 days²
 - 3 days no different than 8³
- Shorter courses are associated with:
 - \downarrow mortality (RR 0.52, 95% CI 0.33-0.82)⁴
 - \downarrow adverse events (RR 0.73, 95% CI 0.55-0.97)⁴


1. Mandell LA. Clin Infect Dis. 2007

2. Uranga A. JAMA Intern Med. 2016

3. el Moussaoui R. BMJ. 2006

4. Tansarli G. Antimicrob Agents Chemother. 2018

Treatment of pneumonia usually requires 5-7 days therapy


	Antibiotics	
First line	Clarithromycin Clarithromycin XL Azithromycin Doxycycline Amoxicillin (1g PO TID)	
First line, if comorbidities	Amoxicillin Amoxicillin/clavulanate	 Clarithromycin Clarithromycin XL Azithromycin Doxycycline
Second line	Any option in “first line, if comorbidities” Levofloxacin Moxifloxacin	



S. pneumoniae azithromycin resistance in Quebec is ~20%.

Community-acquired intraabdominal infections have predictable bacteria

Organisms Identified in 1237 Microbiologically Confirmed Complicated Intra-Abdominal Infections



Adapted from Solomkin JS. Clin Infect Dis. 2010
Chow, AW. Can J Infect Dis Med Microbiol. 2010

Reassess Opportunities to Step-Down Antibiotics Throughout Treatment

Initial Empiric Therapy

Cefazolin + metronidazole

Ceftriaxone + metronidazole

Piperacillin-tazobactam



Targeted Therapy (If Applicable)

Culture results: polymicrobial
vs. monomicrobial

Resistant organism (e.g.
Enterococcus, Candida)

Source control success



Oral Step-down

Amoxicillin-clavulanate

Ciprofloxacin + metronidazole

Shorter Antibiotic Durations Are Safe for Source-Controlled IAIs

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Trial of Short-Course Antimicrobial Therapy for Intraabdominal Infection

R.G. Sawyer, J.A. Claridge, A.B. Nathens, O.D. Rotstein, T.M. Duane, H.L. Evans,

STOP-IT Trial: “Study To Optimize Peritoneal Infection Therapy”

- No difference between 4 days vs. 8 days
- 30-day outcomes: recurrent intraabdominal infection, surgical-site infection, death

Uncomplicated Cystitis



Table 1a: E. coli resistance against first-line agents in Quebec

Nitrofurantoin	Fosfomicin
5-10%	<5%
TMP-SMX	Trimethoprim
15-20%	N/A (see TMP-SMX)



Table 1b: E. coli resistance against second-line agents in Quebec

Ciprofloxacin	B-lactams
10-15%	Variable



>75% cases

E. coli

Other agents

E. faecalis

S. saprophyticus

K. pneumoniae

First Line UTI Agents Have Limitations

Nitrofurantoin

- **Ineffective:**
 - Pyelonephritis
 - CAUTI
 - CKD (eGFR <40)
- **Avoid:**
 - T3 pregnancy

Fosfomycin

- **Ineffective:**
 - Pyelonephritis
 - CAUTI
 - *S. saprophyticus*
- **Limitations:**
 - *E. coli* and *E. faecalis* only
 - Susceptibility testing access

TMP-SMX

- **Ineffective:**
 - Variable local resistance
- **Avoid:**
 - Pregnancy (category C)
 - Rash
 - AKI
 - Hyperkalemia
 - Kernicterus

Fluoroquinolones Are Not Benign

First FQ Introduced

Boxed warning:
worsening
myasthenia gravis

FDA enhanced label warning:
possible permanent side effects
– joint pain, tendon rupture,
tendinitis, anxiety, depression,
altered mental status

1962

2008

2011

2013

2016


2018

Black box warning:
tendinitis and tendon
rupture

Updated labeling:
potentially
irreversible
peripheral
neuropathy

**Safety
communication:**
adverse psychiatric
side-effects &
hypoglycemic risks

Shorter Treatment for Uncomplicated Pyelonephritis is Effective

 **Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial**

Torsten Sandberg, Gunilla Skoog, Anna Bornefalk Hermansson, Gunnar Kahlmeter, Nils Kuylenstierna, Anders Lannergård, Gisela Otto, Bo Settergren, Gunilla Stridh Ekman

A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis



Miriam T. Fox, BS,^a Michael T. Melia, MD,^b Rebecca G. Same, MD,^c Anna T. Conley, BA,^d Pranita D. Tamma, MD, MHS^e
^aDepartment of Medicine, ^bDivision of Infectious Diseases, Department of Medicine, and ^cDepartment of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Md; ^dDepartment of Medicine, The University of Maryland School of Medicine, Baltimore; ^eDivision of Pediatric Infectious Diseases, Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Md.

Treat UTI According to Complexity

Uncomplicated
cystitis

3-5 days

Uncomplicated
pyelonephritis

7 days

Complicated
cystitis

5-7 days

Complicated
pyelonephritis

7-14 days

(Exceptionally ...)

WHEN IS SHORTER NOT BETTER?

Specific infections usually require longer treatment

- Deep-seated infections
 - Source control is key
 - ≥ 4 weeks for bone, joint, endovascular infections
 - Some RCT evidence (e.g. DAPITO trial, 12 weeks for prosthetic knee infections)
- Chronic infections
 - 2 weeks for acute prostatitis
 - 4 to 6 weeks for chronic prostatitis
- Drug-resistant infections

KEY MESSAGES

Shorter Antibiotic Courses are Safe and Effective

3-5 days

- Uncomplicated cystitis
- Source-controlled intra-abdominal

5-7 days

- Odontogenic
- Rhinogenic
- Skin & soft tissue
- AECOPD
- Pneumonia
- Source-controlled intra-abdominal
- Complicated cystitis
- Uncomplicated pyelonephritis

>7 days

- Unresolving skin & soft tissue
- Unresolving pneumonia
- Intra-abdominal, not source-controlled
- Complicated pyelonephritis

Choosing Wisely promotes responsible antimicrobial prescribing

- Using antimicrobials only when indicated
 - Don't treat viruses
- Selecting less C. difficile prone antibiotics
 - Use fluoroquinolones and clindamycin judiciously
- Clarify antibiotic allergies
 - Penicillin allergy de-labelling
- IV-to-PO switch
 - Use oral forms of highly bioavailable agents

Guideline & Resource Links

- Choosing Wisely
 - <http://www.choosingwisely.org/>
 - <https://choosingwiselycanada.org/>
- INESSS Guidelines
 - <https://www.inesss.qc.ca/en/publications/inessss-guides.html>
 - <https://itunes.apple.com/ca/app/inesss-guides/id1206046869>
 - https://play.google.com/store/apps/details?id=com.inesss&hl=fr_CA
- IDSA Guidelines
 - [https://www.idsociety.org/practice-guidelines/#/date na dt/DESC/0/+/](https://www.idsociety.org/practice-guidelines/#/date%20na%20dt/DESC/0/+/)

References

- Choosing Wisely. <http://www.choosingwisely.org/>. Accessed November 7, 2018.
- Choosing Wisely Canada. <https://choosingwiselycanada.org/>. Accessed November 7, 2018.
- Public Health Agency of Canada (PHAC). Canadian antimicrobial resistance surveillance system – report 2016. <https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/drugs-health-products/antibiotic-resistance-antibiotique/antibiotic-resistance-antibiotique-2016-eng.pdf>. Accessed November 9, 2018.
- Spectrum, localized antimicrobial stewardship. <http://www.spectrum.md/>. Accessed November 9, 2018
- Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events With Antibiotic Use in Hospitalized Patients. *JAMA Intern Med.* 2017;177(9):1308-1315.
- Hartley S, Valley S, Kuhn L, et al. Inappropriate testing for urinary tract infection in hospitalized patients: an opportunity for improvement. *Infect Control Hosp Epidemiol.* 2013;34(11):1204-7.

References

- High KP, Bradley SF, Gravenstein S, Mehr DR, Quagliarello VJ, Richards C, Yoshikawa TT. Clinical Practice Guideline for the Evaluation of Fever and Infection in Older Adult Residents of Long-Term Care Facilities: 2008 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2009;48(2):149–171.
- Leis JA, Rebick GW, Daneman N, Gold WL, Poutanen SM, Lo P, Larocque M, Shojania KG, McGeer A. Reducing Antimicrobial Therapy for Asymptomatic Bacteriuria Among Noncatheterized Inpatients: A Proof-of-Concept Study. *Clin Infect Dis*. 2014;58(7):980–983.
- INESSS. Urinary tract infections in adults.
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Outils/GUO/Anglo/Guide_InfectionUrinaire_EN_WEB.pdf. Accessed November 9, 2018.
- https://www.accessdata.fda.gov/drugsatfda_docs/Label/2016/019537s086lbl.pdf. Accessed November 7, 2018.
- <https://www.fda.gov/downloads/Drugs/DrugSafety/UCM513019.pdf>. Accessed November 7, 2018.
- <https://www.fda.gov/downloads/Drugs/DrugSafety/UCM612834.pdf>. Accessed November 7, 2018.

References

- INSPQ. Antibiogramme cumulatif de pathogenes d'interet au laboratoire de sante publique du Quebec.
https://www.inspq.qc.ca/sites/default/files/publications/2327_antibiogramme_cumulatif_pathogenes.pdf. Accessed November 9, 2018.
- INESSS. Cellulitis in adults.
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Outils/GUO/Anglo/Guide_Cellulite_Adulte_WEB_EN.pdf. Accessed November 9, 2017.
- INESSS. Acute rhinosinusitis in adults.
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Outils/GUO/Anglo/Guide_Rhinosinusite_Adulte_EN_WEB.pdf Accessed November 9, 2018.
- Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJC, Hicks LA, Pankey GA, Seleznick M, Volturo G, Wald ER, File TM. IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. *Clin Infect Dis*. 2012;54(8):e72–e112.
- INESSS. Acute exacerbation of COPD (AECOPD).
https://www.inesss.qc.ca/fileadmin/doc/CDM/UsageOptimal/Guides-seriel/Guide_EAMPOC-EN.pdf. Accessed November 9, 2018.
- INESSS. Community-acquired pneumonia in adults.
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Outils/GUO/Anglo/Guide_Pneumo_Adulte_EN_Web.pdf. Accessed November 9, 2018.